Atrial fibrillation (AF) is the most common arrhythmia impacting humans--one in four adults over the age of 40 will experience AF. There has been a dramatic evolution in the role of ablation for the treatment of AF. In recent years, there has been expansion in the role of ablative energy sources (including thermal energy as well as pulsed field ablation). While there has been significant technological development, overall success after AF ablation remains limited. The goal of this study is to evaluate non-procedural factors (e.g., patient characteristics, cardiac and non-cardiac comorbidities, and medication use) with success after AF ablation.

To assess rates and causes for reshospitalization after AF ablation.

The Truven Health MarketScan Research Databases capture person-specific clinical utilization, expenditures, and enrollment across inpatient and outpatient. We will query the database for all pulmonary vein isolation (PVI) procedures and determine subsequent rates of hospitalization.

STATA, SAS (Biostatistician is part of the project team.)

Heart Rhythm Society (HRS), American College of Cardiology (ACC), American Heart Association (AHA)